This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AMAG Pharmaceuticals' CEO Presents IDA-301 Data (Transcript)

The agenda for our call today will be brief. Bill Heiden, our CEO will provide a review of the Phase III registration program for Feraheme. Lee Allen, our Chief Medical Officer will review the preliminary data from the study reported today, and Bill will close the prepared remarks and we’ll open the call for Q&A. Frank Thomas, our Chief Operating Officer, is also with us today. With that I’ll now turn the call over to Bill.

Bill Heiden

Thank you, Amy, and thanks to all of you for joining us here this morning. Before we jump into the data I thought it would be helpful to outline the scope of our Feraheme Phase III program and some of the history behind the design of the clinical program.

The final design of this registration program emerged after detailed discussions regarding endpoints, comparators, and sizing of the trials among other things with both US and EU regulatory authorities. The program consists of two Phase III trials, trials that we call IDA-301 and IDA-302, and an extension study called IDA-303 which evaluates repeat dosing. We initiated the program in 2010 and completed enrollment earlier this year. The data from IDA-301 and IDA-302 will be the basis of our SNDA submission to the FDA for a broad IDA indication which we plan to submit by the end of the year.

Takeda is responsible for filing the broad indication in their territories and we expect that they will be filling in the EU sometime in 2013. So with that brief background I’m now going to turn it over to Lee who’s going to review the data. Lee?

Lee Allen, MD

Thank you, Bill, and thank you to those of you who have joined us this morning on the call. As Bill mentioned, today we reported preliminary top-line results from the IDA-301 study, the second of two Phase III studies that make up our global registrational program for Feraheme for the treatment of iron deficiency anemia regardless of the underlying cause. In this program, we have now treated more than 1000 broad iron deficiency anemia patients who had a history of unsatisfactory response to oral iron with Feraheme. As we’ll discuss today we are very pleased with the results that have been achieved.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.50 -3.40%
FB $116.52 7.00%
GOOG $690.00 -2.20%
TSLA $248.07 -1.40%
YHOO $36.54 -1.10%


Chart of I:DJI
DOW 17,816.20 -225.35 -1.25%
S&P 500 2,076.57 -18.58 -0.89%
NASDAQ 4,810.8720 -52.2690 -1.07%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs